PolyPid Ltd. (PYPD) – What Are Researchers Thinking About This Stock?

Shares of PolyPid Ltd. (NASDAQ:PYPD) have been given an average recommendation of “Moderate Buy” by the five brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $11.00.

A number of brokerages have recently weighed in on PYPD. Craig Hallum set a $12.00 price target on PolyPid in a report on Wednesday, July 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of PolyPid in a research note on Friday, September 18th. HC Wainwright restated a “buy” rating and set a $13.00 price objective on shares of PolyPid in a research report on Tuesday, July 21st. Finally, Oppenheimer initiated coverage on PolyPid in a research report on Tuesday. They set an “outperform” rating and a $10.00 price objective for the company.

Institutional Trading of PolyPid

Institutional investors have recently made changes to their positions in the stock. B. Riley Wealth Advisors Inc. increased its position in PolyPid by 32.7% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 20,085 shares of the company’s stock worth $106,000 after purchasing an additional 4,955 shares during the last quarter. HighTower Advisors LLC acquired a new stake in shares of PolyPid during the 2nd quarter valued at about $56,000. AXQ Capital LP acquired a new stake in shares of PolyPid during the 2nd quarter valued at about $87,000. Renaissance Technologies LLC bought a new stake in shares of PolyPid in the 1st quarter valued at approximately $81,000. Finally, Connective Capital Management LLC bought a new stake in shares of PolyPid in the 2nd quarter valued at approximately $343,000. 26.47% of the stock is currently owned by institutional investors and hedge funds.

PolyPid Stock Performance

PolyPid stock opened at $5.29 on Tuesday. PolyPid has a 52 week low of $3.40 and a 52 week high of $5.73. The firm has a market capitalization of $100.93 million, a price-to-earnings ratio of -3.57 and a beta of 1.38. The company has a 50 day moving average price of $5.13 and a 200 day moving average price of $4.71.

PolyPid (NASDAQ:PYPD) last announced its earnings results on Wednesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.03. Equities analysts forecast that PolyPid will post -0.92 earnings per share for the current fiscal year.

About PolyPid

PolyPid Ltd. (NASDAQ: PYPD) is a clinical-stage biopharmaceutical company focused on developing locally administered therapies designed to provide controlled and sustained drug release at treatment sites. The company’s technology is intended to maintain therapeutic drug concentrations over extended periods while limiting systemic exposure.

PolyPid’s lead product candidate is D-PLEX100, an investigational formulation based on doxycycline and the company’s proprietary PLEX polymeric matrix.